Price (delayed)
$24.46
Market cap
$2.97B
P/E Ratio
17.72
Dividend/share
N/A
EPS
$1.38
Enterprise value
$2.46B
Catalyst Pharmaceuticals is a commercial-stage biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating, chronic neuromuscular and neurological diseases, including Lambert-Eaton myasthenic syndrome (LEMS), anti-MuSK
There are no recent dividends present for CPRX.
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from and Sharadar.